Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
COVID-19: early-phase trial registry
68 of 299 indexed COVID-19 trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #30 of 28,707 conditions by registered trial count.
299 US clinical trials · 68 currently recruiting · #30 of 28,707 conditions by registered trial count
COVID-19: 299 US clinical trials tracked, 68 recruiting.
COVID-19 is the subject of 299 registered US clinical trials on ClinicalTrials.gov, 68 of them currently open to new participants. 42 are in Phase 3-4 (later-stage) and 83 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 16 of these trials.
Enrollment posture brief
Registry condition covid-19
OPEN 68 | RECR 23% | LATE 42 | EARLY 83 | RANK #30 | SPON 16
Volume-matched condition peers
Nearest open-share peer: Hypogonadism (23% recruiting · 22 trials)
COVID-19 lists 68 open slots (23% of 299 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for COVID-19 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
COVID-19 is recruiting below its size-band peers.
68 of 299 indexed trials (22.7%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of COVID-19 trials is spread across many organizations.
National Institute of Allergy and Infectious Diseases (NIAID) accounts for 16 of 299 trials (5.4%). 173 distinct sponsors appear on at least one study for this condition label.
-
Typical COVID-19 enrolment sits around 245 participants.
Median target enrolment is 245 among the 299 trials that report a genuine target (sentinel values excluded). 96 of those (32.1%) plan for fewer than 100 participants.
-
COVID-19 splits between interventional and observational designs.
196 interventional and 103 observational studies make up this index (65.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
299 total, page 2 of 6
A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses
Kara Chew
NCT06810934
A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19.
ModeX Therapeutics, An OPKO Health Company
NCT07445971
Imaging Immune Activation in COVID-19
CellSight Technologies
NCT04815096
A Study of Post COVID-19 Mechanisms for Chronic Lung Sequelae
Mayo Clinic
NCT06006884
Music Mindfulness Study 2a.
Yale University
NCT06505226
The Measurement of Chemicals in Exhaled Breath Can Identify If a Person is Infected with COVID-19
N5 Sensors
NCT06571136
Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
Henry M. Jackson Foundation for the Advancement of Military Medicine
NCT07287137
Impact of the Coronavirus (COVID-19) on Patients With Cancer
Stanford University
NCT04330521
Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients
University of California, Davis
NCT05060991
Convalescent Plasma as a Possible Treatment for COVID-19
University of Illinois at Chicago
NCT04442191
Evaluating the Impact of Social Music
Yale University
NCT06513910
Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure
Jon Simmons
NCT04445285
Defibrotide for the Treatment of Severe COVID-19
Brigham and Women's Hospital
NCT04652115
A Nasal Treatment for COVID-19
Indiana University
NCT05799521
A Study of Healthy Microbiome, Healthy Mind
Mayo Clinic
NCT06020703
Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise
Ohio State University Comprehensive Cancer Center
NCT04427566
Arginine Replacement Therapy in COVID-19
Emory University
NCT05855330
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
University of California, San Francisco
NCT05530317
COVID-19 Symptom Tracker
King's College London
NCT04331509
Duke COVID-19 Shared Data and Specimen Repository
Duke University
NCT04368234
A Study to Learn How Paxlovid [Nirmatrelvir-ritonavir/PF-07321332] Works in COVID-19 Patients Who Are Elderly or Have Medical Conditions.
Pfizer
NCT07261085
COVID-19 & Psychiatry: A Retrospective Chart Review
Northwestern University
NCT05244096
A Rapid Diagnostic of Risk in Hospitalized Patients Using Machine Learning
AgileMD
NCT05893420
COVID-19 and Cancer Consortium Registry
Vanderbilt-Ingram Cancer Center
NCT04354701
A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection
Vaxart
NCT06672055
Pediatric COVID Outcomes Study (PECOS)
Children's National Research Institute
NCT04830852
Improving Health Equity for COVID-19 Vaccination for At-risk Populations Using Online Social Networks
University of Pennsylvania
NCT04779827
Project REMOTE (REimagining Measurements and Operations of Translational Endpoints)
Biomedical Advanced Research and Development Authority
NCT06776367
Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years
Novavax
NCT05468736
Retail COVID-19 Study
Biomedical Advanced Research and Development Authority
NCT06761612
COVID-19 CHAMPS Study of Healthcare, First Responder and Service Workers
Villanova University
NCT04370821
Study of VYD2311 for the Prevention of COVID-19
Invivyd
NCT07298434
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
QuantumLeap Healthcare Collaborative
NCT04488081
COVID-19 Reactogenicity
Marcel Curlin
NCT07051031
COVID-19 Quick Start - Test and Treat in Africa
Duke University
NCT06360783
A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza
Pfizer
NCT05160636
Engaging Staff to Improve COVID-19 Vaccination Response at Long-Term Care Facilities
Kaiser Permanente
NCT05449418
Risk Stratification of COVID-19 Using Urine Biomarkers
National Center for Global Health and Medicine, Japan
NCT04681040
A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years
BioNTech SE
NCT07069309
Safety and Immunogenicity of NVX-CoV2705
Sanofi
NCT07079670
Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States
Novavax
NCT06633835
A Longitudinal Study of COVID-19 Sequelae and Immunity
National Institute of Allergy and Infectious Diseases (NIAID)
NCT04411147
Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs
NDRI-USA
NCT04924803
Long Term Outcomes of Patients With COVID-19
University of Chicago
NCT04360538
Post Acute Sequelae of COVID-19
Vanderbilt University Medical Center
NCT04964115
A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults
CyanVac
NCT06742281
Working Towards Empowered Community-driven Approaches to Increase Vaccination and Preventive Care Engagement
University of California, San Diego
NCT05841810
ARMOR-Household: Characterizing Transmission of COVID-19 in Households of SARS-CoV-2 Index Cases
Columbia University
NCT05467917
A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19
BioNTech SE
NCT07222384
SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies
The Geneva Foundation
NCT05765396
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 28 |
| Phase 2 | 55 |
| Phase 3 | 31 |
| Phase 4 | 11 |
Top Sponsors
Named interventions
Most-linked intervention names on COVID-19 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on COVID-19 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this COVID-19 page
299 registered trials, 68 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 68 COVID-19 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Institute of Allergy and Infectious Diseases (NIAID) sponsors the most COVID-19 trials on record, review their full trial history before evaluating a specific study. See National Institute of Allergy and Infectious Diseases (NIAID)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This COVID-19 condition card totals 299 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.